Fig. 4
From: High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma
Hit selection strategy applied to the primary screen. (a) A total of 6710 compounds were screened and viability assessed across 4 cell lines. Based on this data, we subsequently reduced the library scale by including only agents in phase 1 development trials through to FDA approved and kinase and epigenetic. (b) Putative hits were triaged in the initial filtering step based on high and moderate-confidence filtering strategies, resulting in 122 compound hits. (c) High confidence hits were further selected for compounds demonstrating cytotoxicity (robust Z-score ≤ -2) at 0.1 µM.
